TGF-β/Smads信号通路在心肌纤维化发生和治疗中应用前景的研究进展  

The research progress of TGF-β/Smads signal pathway in the treatment of myocardial fibrosis and its application

作　　者：陈蓉[1,2] 谢梅林[2] 

机构地区：[1]苏州大学附属第一医院药学部,江苏苏州215006 [2]苏州大学医学部药理系,江苏苏州215123

出　　处：《中国药理学通报》2012年第9期1189-1192,共4页Chinese Pharmacological Bulletin

基　　金：江苏省普通高校研究生科研创新计划项目(No CX10B_056Z);苏州大学青年教师自然科学基金项目(NoSDY2011A39)

摘　　要：心肌纤维化(MF)是多种心脏疾病发展到一定阶段的共同病理改变,是心肌重构的主要表现之一。这种病理变化存在于多种心血管疾病中,与心律失常、心力衰竭等疾病密切相关。转化生长因子-β(TGF-β)在MF的发生和发展中起着重要作用。TGF-β/Smads信号通路是TGF-β发挥生物学作用的主要通路,其分子组成与分子调节复杂,现将它在MF发生和治疗中应用前景作一综述。Myocardial fibrosis （MF） is a common pathological change that a variety of cardiac diseases develop to a certain stage, which is one of the main performance of myocardial remodeling. This pathological change exists in many cardiovascu- lar diseases and associates with arrhythmia, heart failure and other closely related diseases. Transforming growth factor- β（TGF-β） plays an important role in the occurrence and development of MF. TGF-β/Smads signal pathway is the major pathwayin which TGF-β plays a biological role, and its molecular compo- sition and molecular regulation are complex. In this paper, the signal pathway in the treatment of MF and its application are reviewed.

关 键 词：心肌纤维化 转化生长因子-Β 转化生长因子-β受 体 受体激活型Smads 共同介质Smads 抑制型Smads 

分 类 号：R05[医药卫生] R349.1